Site is under maintenance mode. Please wait few min!

Site is under maintenance mode. Please wait few min!

NUCLEIC ACID THERAPEUTICS RESEARCH

Research Focus

Associate Professor Rakesh Veedu and his team’s research is focused on novel functional nucleic acid-based biotechnologies for developing target–specific therapies for neurological diseases, inherited/genetic disorders, and solid cancers.

Specifically, research involves the development and applications of:

Nucleic acid aptamers
Antisense oligonucleotides
siRNA and antimiRs
DNAzymes

Associate Professor Veedu is a Perron Institute McCusker Research Fellow based at the Centre for Molecular Medicine and Innovative Therapeutics at Murdoch University, and is an Honorary Fellow at the University of Queensland’s School of Chemistry and Molecular Biosciences.

Perron Research News

Perron Institute

17 December 2020

Leanne Jiang wins national three-minute thesis prize

Raine Foundation

30 November 2020

Raine Foundation travel grant for Alex Tang

26 November 2020

Darren Clarke graduates and off to Montreal

17 November 2020

Bill Carroll nominated for Western Australian of the Year

27 October 2020

Study finds new gene that causes osteosarcoma

Perron Institute

21 September 2020

$1 million grant from FightMND for potential MND treatment

29 July 2020

Medical Director shares own story for World Brain Day PD

Anthony-and-Loren-Perron-Institute

29 July 2020

New collaboration in pursuit of personalised therapies for MND

21 July 2020

MND family carers at greater risk of prolonged grief impacts

Merrilee Needham Perron Institute

Perron Institute

26 June 2020

WA led Myositis study attracts $1.88 million federal grant

Perron Institute

19 June 2020

Understanding quality of life perceptions in motor neurone disease

Rakesh Veedu lab

16 June 2020

New grant to develop accurate and fast paper test for COVID-19

16 June 2020

Murdoch and Monash funded for potential COVID-19 treatment

9 June 2020

Global approach to COVID-19 paper highlighted

Perron Institute

8 June 2020

Bryant Stokes receives Queen’s Birthday Honours

Prof Samar Aoun

Perron Institute

8 June 2020

Reviewing perceptions of palliative care in WA

22 April 2020

COVID-19 resources for people living with neurological conditions

Prof Samar Aoun Perron Institute

Perron Institute

22 April 2020

Improving bad news delivery for better patient outcomes

Black Swan team with Steve Arnott Perron Institute

Perron Institute

19 March 2020

Partnership established to expedite MND treatment

Bhedita Seewoo Perron Institute best paper winner 2020

Perron Institute

31 January 2020

Student award winners announced

31 January 2020

Byron Kakulas Prestige Scholarship recipients

20 December 2019

Second muscular dystrophy drug approved by US FDA

13 December 2019

Welcome research fellow Samantha Winter

7 November 2019

MND grant received from MND Research Institute Australia

22 August 2019

Recruiting for Huntington’s clinical trials in WA

Research Team Leader

31 January 2015

Associate Professor Rakesh Veedu PhD

Research Team Achievements

All/Grants/Publications

1 January 2019

McCusker Charitable Foundation Fellowship, Veedu RN, 2015-2019 $600,000

6 February 2018

Chemical Communication 54: 4593-4596.

31 January 2018

Scientific Reports. doi:10.1038/s41598-018-22902-9

31 January 2018

Cancers. DOI: 10.3390/cancers10010019

31 January 2017

Theranostics, 7, 3933-3947. doi:10.7150/thno.21529

31 January 2017

Molecular Therapy Nucleic Acids, 9, 155–161. doi: 10.1016/j.omtn.2017.09.002

31 January 2017

RSC Advances, 7, 54542-54545. DOI: 10.1039/C7RA10964D

31 January 2017

Molecules, 22(10), 1770. DOI: 10.3390/molecules22101770

31 January 2017

Theranostics, 7, 3933-3947. doi:10.7150/thno.21529 [Rank: Q1; IF = 8.712]

31 January 2017

Molecules, 22(10), 1770. DOI: 10.3390/molecules22101770 [Rank: Q1; MDPI]

31 January 2017

RSC Advances, (2017) 10, 34049-34052. DOI: 10.1039/C7RA06091B

31 January 2017

ChemBioChem. (2017) DOI: 10.1002/cbic.201700276

31 January 2017

Scientific Reports (2017) 7, 1613. doi:10.1038/s41598-017-01559-w

31 January 2016

Molecules, 21, 1582.

31 January 2016

RNA Biology, 13(12):1232-1245.

31 January 2016

Chemical Communication, 52, 13467- 13470

31 January 2016

Australian Journal of Chemistry, 69, 1108–1116

1 January 2016

Ghrelin axis as a target for prostate cancer therapy, NHMRC Project Grant, 2014-2016 $566,226

1 January 2016

Western Australia Dept. of Health – Merit Award 2016, $75,000

1 January 2016

Multiple Sclerosis Research Australia (MSRA) – Incubator Grant 2016, $24,850

6 February 2015

Current Topics in Medicinal Chemistry. 2015;15(12):1065.

31 January 2015

Chemical Communications 51: 9499-9502. [IF = 6.718].

31 January 2015

Chemical Reviews, In Press (DOI: 10.1021/cr5002832). [IF = 45.66].

31 January 2015

RNA Biology 12: 412-425. [IF = 5.377].

31 January 2015

Trends in Molecular Medicine, 2015 1471-4914/

31 January 2015

RSC Advances 5: 29008-29016. [IF = 3.7].

31 January 2015

Current Medicinal Chemistry, In Press (PMID: 25723512) [IF = 3.71].

31 January 2015

Curr Topic Med Chem, 2015;15(12):1115-24. [IF = 3.45].

31 January 2015

Pan Stanford Publishing Pte Ltd, Singapore, 2015,

1 January 2011

University of Queensland Teaching Fellowship, ResTeach, $23,480; 2011

1 January 2011

University of Queensland Early Career Research Grant, $22,000; 2011

1 January 2010

University of Queensland Research Fellowship, $278,000; 2010-2013

1 January 2019

McCusker Charitable Foundation Fellowship, Veedu RN, 2015-2019 $600,000

1 January 2016

Ghrelin axis as a target for prostate cancer therapy, NHMRC Project Grant, 2014-2016 $566,226

1 January 2016

Western Australia Dept. of Health – Merit Award 2016, $75,000

1 January 2016

Multiple Sclerosis Research Australia (MSRA) – Incubator Grant 2016, $24,850

1 January 2011

University of Queensland Teaching Fellowship, ResTeach, $23,480; 2011

1 January 2011

University of Queensland Early Career Research Grant, $22,000; 2011

1 January 2010

University of Queensland Research Fellowship, $278,000; 2010-2013

6 February 2018

Chemical Communication 54: 4593-4596.

31 January 2018

Scientific Reports. doi:10.1038/s41598-018-22902-9

31 January 2018

Cancers. DOI: 10.3390/cancers10010019

31 January 2017

Theranostics, 7, 3933-3947. doi:10.7150/thno.21529

31 January 2017

Molecular Therapy Nucleic Acids, 9, 155–161. doi: 10.1016/j.omtn.2017.09.002

31 January 2017

RSC Advances, 7, 54542-54545. DOI: 10.1039/C7RA10964D

31 January 2017

Molecules, 22(10), 1770. DOI: 10.3390/molecules22101770

31 January 2017

Theranostics, 7, 3933-3947. doi:10.7150/thno.21529 [Rank: Q1; IF = 8.712]

31 January 2017

Molecules, 22(10), 1770. DOI: 10.3390/molecules22101770 [Rank: Q1; MDPI]

31 January 2017

RSC Advances, (2017) 10, 34049-34052. DOI: 10.1039/C7RA06091B

31 January 2017

ChemBioChem. (2017) DOI: 10.1002/cbic.201700276

31 January 2017

Scientific Reports (2017) 7, 1613. doi:10.1038/s41598-017-01559-w

31 January 2016

Molecules, 21, 1582.

31 January 2016

RNA Biology, 13(12):1232-1245.

31 January 2016

Chemical Communication, 52, 13467- 13470

31 January 2016

Australian Journal of Chemistry, 69, 1108–1116

6 February 2015

Current Topics in Medicinal Chemistry. 2015;15(12):1065.

31 January 2015

Chemical Communications 51: 9499-9502. [IF = 6.718].

31 January 2015

Chemical Reviews, In Press (DOI: 10.1021/cr5002832). [IF = 45.66].

31 January 2015

RNA Biology 12: 412-425. [IF = 5.377].

31 January 2015

Trends in Molecular Medicine, 2015 1471-4914/

31 January 2015

RSC Advances 5: 29008-29016. [IF = 3.7].

31 January 2015

Current Medicinal Chemistry, In Press (PMID: 25723512) [IF = 3.71].

31 January 2015

Curr Topic Med Chem, 2015;15(12):1115-24. [IF = 3.45].

31 January 2015

Pan Stanford Publishing Pte Ltd, Singapore, 2015,